• Johnson & Johnson on May 4, 2026 released results from a new network meta-analysis comparing CAPLYTA as add-on therapy for major depressive disorder against other FDA-approved atypical antipsychotics, using data from 10 registrational trials.
• Findings were already presented in a late-breaking session at 2026 NEI Spring Congress, held May 1-3.
• Analysis ranked CAPLYTA highest across key measures of symptom improvement versus rival adjunctive options, based on indirect comparisons from placebo-controlled studies.
• On tolerability, CAPLYTA showed no meaningful weight gain versus placebo in the pooled analysis, while sedation-related side effects remained a risk across evaluated add-on treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.